MRVI
Maravai LifeSciences Holdings, Inc.
MRVI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
MRVI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRVI's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
MRVI PE Valuation
MRVI has no meaningful PE right now: it lost money over the past year.
MRVI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect MRVI's losses to shrink, with revenue growing.
MRVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | +$0.44 |
| Q2 2026 | -$0.52 | +$0.87 |
| Q1 2026 | -$0.71 | +$0.46 |
| Q4 2025 | -$0.90 | +$0.15 |
| Q3 2025 | -$0.87 | +$0.77 |
| Q2 2025 | -$1.39 | -$0.40 |
| Q1 2025 | -$1.17 | -$0.18 |
| Q4 2024 | -$1.05 | -$0.15 |
MRVI is still losing money, but far less than before: $0.43 per share over the past year, against $1.64 at its worst in late 2024.
MRVI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.9M | +10% |
| Q2 2026 | $51.4M | +8.5% |
| Q1 2026 | $65.8M | +41% |
| Q4 2025 | $49.9M | -12% |
| Q3 2025 | $41.6M | -36% |
| Q2 2025 | $47.4M | -35% |
| Q1 2025 | $46.9M | -27% |
| Q4 2024 | $56.6M | -24% |
MRVI's revenue is recovering but still below its 2022 peak: $46M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | +54 points |
| Q2 2026 | -29% | +111 points |
| Q1 2026 | -3.3% | +102 points |
| Q4 2025 | -118% | -51 points |
| Q3 2025 | -99% | +161 points |
| Q2 2025 | -140% | -127 points |
| Q1 2025 | -105% | -76 points |
| Q4 2024 | -67% | -57 points |
MRVI's operating margin was −45% last quarter, up 54 points from the same quarter a year ago.
MRVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.5M | +$22.6M |
| Q2 2026 | $3.6M | +$16.8M |
| Q1 2026 | $4.2M | +$18.9M |
| Q4 2025 | -$24.9M | -$4.4M |
| Q3 2025 | -$18.1M | -498% |
| Q2 2025 | -$13.1M | -267% |
| Q1 2025 | -$14.6M | -$493K |
| Q4 2024 | -$20.5M | -$11.5M |
MRVI's free cash flow was −$13M over the past year, against −$66M the year before.
MRVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.1M shares |
| 1 year | +3% | +4.4M shares |
| 3 years | +13% | +17.1M shares |
| 5 years | +33% | +36.8M shares |
| Available history | +54% | +52.4M shares |
MRVI has 149M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
MRVI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -5.9x | Net Cash |
| Q3 2023 | -0.5x | Net Cash |
| Q2 2023 | -0.2x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.1x | Net Cash |
| Q2 2022 | -0.0x | Net Cash |
| Q1 2022 | 0.2x | Very low |
MRVI has more cash than debt.
MRVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 55.9 | Neutral |
MRVI's weekly RSI is 59 (neutral) and its Stochastic is 56 (neutral).
MRVI PE vs Healthcare Sector
| Metric | MRVI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRVI has no meaningful PE right now: it lost money over the past year.
MRVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.51 | 2.3% above |
| 20 week MA | $7.09 | 8.3% above |
| 50 week MA | $5.11 | 50% above |
| 100 week MA | $4.09 | 88% above |
| 200 week MA | $6.78 | 13% above |
MRVI has climbed back above all five of its weekly moving averages, and it's now 13% above its 200-week average.
MRVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.9 | $29.7 | -0.5% |
| 2021 | $29.7 | $42.0 | +41% |
| 2022 | $42.0 | $14.0 | -67% |
| 2023 | $14.0 | $6.55 | -53% |
| 2024 | $6.55 | $5.50 | -16% |
| 2025 | $5.50 | $3.27 | -41% |
| 2026 YTD | $3.27 | $7.68 | +135% |
MRVI has finished four years in a row lower, and it's up 135% so far in 2026.